EA201591072A1 - Антитела против pdgfr-бета и их применения - Google Patents

Антитела против pdgfr-бета и их применения

Info

Publication number
EA201591072A1
EA201591072A1 EA201591072A EA201591072A EA201591072A1 EA 201591072 A1 EA201591072 A1 EA 201591072A1 EA 201591072 A EA201591072 A EA 201591072A EA 201591072 A EA201591072 A EA 201591072A EA 201591072 A1 EA201591072 A1 EA 201591072A1
Authority
EA
Eurasian Patent Office
Prior art keywords
beta
pdgfr
antibodies
diseases
applications
Prior art date
Application number
EA201591072A
Other languages
English (en)
Other versions
EA031049B1 (ru
Inventor
Стэнли Дж. Уиганд
Иван Б. Лобов
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201591072A1 publication Critical patent/EA201591072A1/ru
Publication of EA031049B1 publication Critical patent/EA031049B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)

Abstract

Изобретение относится к антителам, которые связываются с рецептором бета полученного из тромбоцитов фактора роста (PDGFR-бета), и к способам их применения. Согласно некоторым вариантам осуществления изобретения антитела представляют собой полностью человеческие антитела, которые связываются в PDGFR-бета человека с высокой аффинностью. Антитела по изобретению применимы для лечения заболеваний и расстройств, ассоциированных с передачей сигнала PDGFR-бета и/или клеточной экспрессией PDGFR-бета, таких как глазные болезни, фиброзные болезни, сосудистые заболевания и злокачественные опухоли.
EA201591072A 2013-01-09 2014-01-07 Антитела против pdgfr-бета и их применения EA031049B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361750437P 2013-01-09 2013-01-09
US201361863452P 2013-08-08 2013-08-08
US201361909421P 2013-11-27 2013-11-27
PCT/US2014/010395 WO2014109999A1 (en) 2013-01-09 2014-01-07 ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF

Publications (2)

Publication Number Publication Date
EA201591072A1 true EA201591072A1 (ru) 2015-12-30
EA031049B1 EA031049B1 (ru) 2018-11-30

Family

ID=50002880

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201591072A EA031049B1 (ru) 2013-01-09 2014-01-07 Антитела против pdgfr-бета и их применения
EA201890143A EA201890143A3 (ru) 2013-01-09 2014-01-07 Антитела против pdgfr-бета и их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201890143A EA201890143A3 (ru) 2013-01-09 2014-01-07 Антитела против pdgfr-бета и их применения

Country Status (22)

Country Link
US (3) US9265827B2 (ru)
EP (1) EP2943218B1 (ru)
JP (1) JP6367233B2 (ru)
KR (1) KR102146692B1 (ru)
CN (1) CN104936614B (ru)
AU (3) AU2014205641B2 (ru)
BR (1) BR112015016312B1 (ru)
CA (1) CA2897383C (ru)
CL (2) CL2015001924A1 (ru)
EA (2) EA031049B1 (ru)
HK (1) HK1214969A1 (ru)
IL (2) IL239552B (ru)
JO (1) JO3405B1 (ru)
MX (1) MX363635B (ru)
MY (1) MY169165A (ru)
NZ (1) NZ709683A (ru)
PH (1) PH12015501493A1 (ru)
SG (2) SG11201505035YA (ru)
TW (1) TWI647239B (ru)
UY (1) UY35258A (ru)
WO (1) WO2014109999A1 (ru)
ZA (1) ZA201504537B (ru)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CA3107182A1 (en) 2013-07-12 2015-01-15 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN113150163A (zh) * 2014-03-21 2021-07-23 X博迪公司 双特异性抗原结合多肽
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2963606A1 (en) 2014-11-10 2016-05-19 F.Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
BR112017009817A2 (pt) 2014-11-10 2018-02-14 Hoffmann La Roche anticorpos anti-il-1beta e métodos de utilização
JP6946184B2 (ja) * 2014-11-10 2021-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｐｄｇｆ−ｂ抗体及び使用法
CN107074941A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 双特异性抗体和用于眼科学的方法
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CN107708732A (zh) * 2015-02-06 2018-02-16 卡德门企业有限公司 免疫调节剂
CN108348572B (zh) 2015-03-31 2021-06-29 日东制药株式会社 含有融合组织穿透肽和抗-vegf制剂的融合蛋白的预防和治疗眼疾的药物组合物
ES2828694T3 (es) 2015-07-29 2021-05-27 Allergan Inc Anticuerpos sólo de cadena pesada frente a ANG-2
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN108366968B (zh) 2015-12-16 2022-02-18 瑞泽恩制药公司 制造蛋白质微粒的组合物和方法
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3478718A4 (en) * 2016-07-01 2020-07-29 Paracrine Therapeutics AB METHOD AND COMPOSITIONS FOR INHIBITING PDGF-CC
EP3500297A1 (en) 2016-08-16 2019-06-26 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN109021104B (zh) * 2017-06-12 2022-08-12 上海睿智化学研究有限公司 一种抗人血小板衍生生长因子β受体的抗体及其应用
KR102659791B1 (ko) 2017-07-06 2024-04-23 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
KR20200103728A (ko) 2017-12-22 2020-09-02 리제너론 파마슈티칼스 인코포레이티드 약물 제품 불순물 특성화를 위한 시스템 및 방법
AU2019215363A1 (en) 2018-01-31 2020-07-23 Regeneron Pharmaceuticals, Inc. System and method for characterizing size and charge variant drug product impurities
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
WO2019168774A1 (en) 2018-02-28 2019-09-06 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
ES2969882T3 (es) 2018-03-19 2024-05-23 Regeneron Pharma Ensayos y reactivos de electroforesis capilar en microchip
GB201806918D0 (en) * 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
CN108586611B (zh) * 2018-04-28 2021-01-26 暨南大学 重组全人源抗破伤风毒素单克隆抗体
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
CA3100035A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
EA202190032A1 (ru) 2018-08-30 2021-03-12 Ридженерон Фармасьютикалз, Инк. Способы определения характеристик белковых комплексов
EP3868781A4 (en) * 2018-10-05 2022-07-06 Seoul National University R & DB Foundation PDGF RECEPTOR ANTIBODIES AND ITS USE
WO2020150491A1 (en) 2019-01-16 2020-07-23 Regeneron Pharmaceuticals, Inc. Methods for characterizing disulfide bonds
US20220143204A1 (en) * 2019-03-08 2022-05-12 Linxis B.V. Internalizing binding molecules targeting receptors involved in cell proliferation or in cell differentiation
TW202108606A (zh) 2019-05-03 2021-03-01 新加坡商新加坡保健服務私人有限公司 代謝性疾病之治療及預防
JP2022532503A (ja) 2019-05-13 2022-07-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された競合的リガンド結合アッセイ
EP4034870A1 (en) 2019-09-24 2022-08-03 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
KR20220104797A (ko) 2019-11-25 2022-07-26 리제너론 파마슈티칼스 인코포레이티드 비수성 에멀전을 이용한 지속 방출 제형
WO2021142086A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
WO2021150558A1 (en) 2020-01-21 2021-07-29 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
AU2021332355A1 (en) 2020-08-31 2023-03-23 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
JP2023541934A (ja) * 2020-09-16 2023-10-04 リンクシス ベスローテン フェンノートシャップ 内在化結合分子
US20220160828A1 (en) 2020-11-25 2022-05-26 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
EP4262757A1 (en) 2020-12-17 2023-10-25 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
US20220228107A1 (en) 2021-01-20 2022-07-21 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
CA3207883A1 (en) 2021-03-03 2022-09-09 Xiaobin Xu Systems and methods for quantifying and modifying protein viscosity
JP2024519407A (ja) 2021-03-26 2024-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 混合プロトコルを作成するための方法およびシステム
WO2022256383A1 (en) 2021-06-01 2022-12-08 Regeneron Pharmaceuticals, Inc. Micropchip capillary electrophoresis assays and reagents
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
IL311527A (en) 2021-09-20 2024-05-01 Regeneron Pharma Methods for controlling antibody heterogeneity
WO2023059800A2 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
CN118076885A (zh) 2021-10-07 2024-05-24 里珍纳龙药品有限公司 pH计校准与校正
CA3236367A1 (en) 2021-10-26 2023-05-04 Michelle Lafond Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
TW202346856A (zh) 2022-03-18 2023-12-01 美商里珍納龍藥品有限公司 分析多肽變體的方法及系統
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA2100559C (en) 1991-01-31 2007-05-22 David Wolf Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
RU2194760C2 (ru) 1991-12-02 2002-12-20 Кор Терапьютикс, Инк. Иммуноглобулиновый полипептид, его фрагмент, композиция, штамм гибридных культивируемых клеток, способ получения полипептида
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5620687A (en) 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
KR101501870B1 (ko) 2003-08-27 2015-03-12 옵쏘테크 코포레이션 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
AU2008242444B2 (en) * 2007-04-17 2013-05-02 Imclone Llc PDGFRBeta-specific inhibitors
CN101801407B (zh) 2007-06-05 2013-12-18 耶鲁大学 受体酪氨酸激酶抑制剂及其使用方法
ES2368876T3 (es) 2007-08-22 2011-11-23 Irm Llc Derivados de 2-heteroarilaminopirimidina como inhibidores de cinasa.
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
DK2274008T3 (da) * 2008-03-27 2014-05-12 Zymogenetics Inc Sammensætninger og fremgangsmåder til hæmning af PDGFRBETA og VEGF-A
WO2010127029A1 (en) 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CN102250249A (zh) 2011-06-18 2011-11-23 常州亚当生物技术有限公司 一种抗VEGF/PDGFRbeta双特异性抗体及其应用

Also Published As

Publication number Publication date
IL245040B (en) 2020-05-31
AU2018202814A1 (en) 2018-05-10
EP2943218A1 (en) 2015-11-18
US20160122433A1 (en) 2016-05-05
AU2017245479C1 (en) 2018-08-16
CA2897383A1 (en) 2014-07-17
IL245040A0 (en) 2016-05-31
AU2018202814B2 (en) 2019-04-18
WO2014109999A1 (en) 2014-07-17
SG10201701308VA (en) 2017-03-30
US9265827B2 (en) 2016-02-23
IL239552B (en) 2019-01-31
JP6367233B2 (ja) 2018-08-01
MY169165A (en) 2019-02-20
TW201441261A (zh) 2014-11-01
PH12015501493B1 (en) 2015-09-28
KR102146692B1 (ko) 2020-08-21
BR112015016312B1 (pt) 2020-12-15
CN104936614B (zh) 2018-09-18
AU2017245479B2 (en) 2018-01-25
CN104936614A (zh) 2015-09-23
NZ709683A (en) 2019-01-25
MX2015008689A (es) 2015-10-05
JO3405B1 (ar) 2019-10-20
SG11201505035YA (en) 2015-07-30
US10023642B2 (en) 2018-07-17
HK1214969A1 (zh) 2016-08-12
CL2018000703A1 (es) 2018-07-06
ZA201504537B (en) 2016-07-27
IL239552A0 (en) 2015-08-31
PH12015501493A1 (en) 2015-09-28
US20170210813A1 (en) 2017-07-27
CA2897383C (en) 2021-07-06
UY35258A (es) 2014-08-29
KR20150103682A (ko) 2015-09-11
TWI647239B (zh) 2019-01-11
JP2016504416A (ja) 2016-02-12
US9650444B2 (en) 2017-05-16
EA201890143A3 (ru) 2018-09-28
EA031049B1 (ru) 2018-11-30
AU2018202814B9 (en) 2019-06-06
MX363635B (es) 2019-03-29
EA201890143A2 (ru) 2018-05-31
AU2017245479A1 (en) 2017-11-02
US20140193402A1 (en) 2014-07-10
EP2943218B1 (en) 2018-08-08
AU2014205641B2 (en) 2017-08-24
CL2015001924A1 (es) 2016-06-10
AU2014205641A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
EA201591072A1 (ru) Антитела против pdgfr-бета и их применения
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
PH12017500402A1 (en) Anti-glucagon antibodies and uses thereof
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
PH12015501656A1 (en) Anti-il-33 antibodies and use thereof
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
PH12016500943A1 (en) Aplnr modulatros and uses thereof
MX2015016111A (es) Anticuerpos anti-b7-h5 y sus usos.
EA201590402A1 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА ПРОТИВ GFRα3 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
MY180157A (en) Antibody formulations and uses thereof
EA201892440A1 (ru) Антитела к tl1a и их применения
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201990978A1 (ru) Антитела против pd-1
MX2015015232A (es) Anticuerpo monoclonal dirigido contra cxcr5.
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения
EA202090128A2 (ru) Антитела против антигена 2 дендритных клеток крови и их применение